Affimed N.VのIPO年
Affimed N.VのIPO年は何ですか。
Affimed N.V.のIPO年は2014です。
IPO年の定義は何ですか。
新規公開株 (IPO)は、企業の株式を通常は機関投資家に販売し、順番に証券取引所で一般市民に販売する株式公開の一種です。
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
NASDAQのセクタHealth CareにおけるIPO年の企業と比べるAffimed N.V
Affimed N.Vは何をしますか。
affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli
Affimed N.Vと類似のipo年
- Australian REIT Income FundのIPO年は2013です。
- Brookfield Asset Management PRF SH CL A SE37のIPO年は2013です。
- Modern MeatのIPO年は2013です。
- Blue Capital Reinsurance LtdのIPO年は2013です。
- Siyata MobileのIPO年は2013です。
- Mirati Therapeutics IncのIPO年は2013です。
- Affimed N.VのIPO年は2014です。
- GlaukosのIPO年は2015です。
- UBS ETFs Public - MSCI ACWI SF UCITS ETFのIPO年は2015です。
- Acasta EnterprisesのIPO年は2015です。
- Faron Pharmaceuticals OyのIPO年は2015です。
- GreenPower Motor CoのIPO年は2015です。
- Sunrun IncのIPO年は2015です。